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Abstract. Optimizing quality of care for malaria and other febrile illnesses is a complex challenge of major public
health importance. To evaluate the impact of an intervention aiming to improve malaria case management on the
health of community children, a cluster-randomized trial was conducted from 2010–2013 in Tororo, Uganda, where
malaria transmission is high. Twenty public health centers were included; 10 were randomized in a 1:1 ratio to intervention
or control. Households within 2 km of health centers provided the sampling frame for the evaluation. The PRIME
intervention included training in fever case management using malaria rapid diagnostic tests (mRDTs), patient-centered
services, and health center management; plus provision of mRDTs and artemether–lumefantrine. Cross-sectional com-
munity surveys were conducted at baseline and endline (N = 8,766), and a cohort of children was followed for approxi-
mately 18 months (N = 992). The primary outcome was prevalence of anemia (hemoglobin < 11.0 g/dL) in children
under 5 years of age in the final community survey. The intervention was delivered successfully; however, no differ-
ences in prevalence of anemia or parasitemia were observed between the study arms in the final community survey or
the cohort. In the final survey, prevalence of anemia in children under 5 years of age was 62.5% in the intervention
versus 63.1% in control (adjusted risk ratio = 1.01; 95% confidence interval = 0.91–1.13; P = 0.82). The PRIME inter-
vention, focusing on training and commodities, did not produce the expected health benefits in community children in
Tororo. This challenges common assumptions that improving quality of care and access to malaria diagnostics will yield
health gains.
INTRODUCTION
Over the past decade, encouraging reductions in malaria
burden have been documented worldwide, after heavy invest-
ment in malaria control measures.1,2 However, these successes
have been achieved primarily in lower transmission settings.3
In Uganda, despite some progress,4 the burden of malaria has
remained high, calling for an expansion in malaria control
efforts.5,6 Provision of good quality care, including accurate
diagnosis and prompt effective antimalarial treatment, is a key
malaria control strategy.7,8 However, health system challenges
limit access to good quality care and contribute to poor prog-
ress on malaria control.9–11 Interventions to improve the qual-
ity of care provided in the public sector, and ultimately to
improve health outcomes, are urgently needed.12 However,
the optimal approach to quality improvement and fever case
management is not clear, particularly in low- and middle-
income countries.9,13,14
Use of rapid diagnostic tests for malaria (mRDTs) to tar-
get antimalarial treatment and improve health outcomes
has been strongly advocated,7,8,15 and mRDTs have been
rapidly scaled up, particularly in Africa.1 Significant prog-
ress has been made toward understanding the performance
and impact of mRDTs in different sites.16,17 However, intro-
ducing mRDTs into clinical settings is not simple, and evi-
dence that mRDTs improve health outcomes is limited.17 The
training package and support supervision implemented along-
side mRDTs appear to be as important as provision of the
tests themselves,18–20 and even if high quality care and accu-
rate diagnosis are provided, patients only stand to benefit if
they choose to access this care.12
In preparation for the PRIME trial, we conducted exten-
sive formative research in Tororo aiming to understand the
local population, barriers to providing high quality health
care, and options for interventions that could be feasibly and
sustainably implemented in the public sector.12,21 On the
basis of this formative research and the priorities identi-
fied by local stakeholders, we developed an intervention to
improve the quality of care delivered for malaria and other
childhood febrile illnesses by training health workers in pub-
lic health centers, and ensuring adequate supplies of mRDTs
and artemisinin-based combination therapies (ACTs).22 The
PRIME study was designed to evaluate the community-level
health impact of the intervention.23 The primary objective
of the trial was to evaluate the impact of the PRIME inter-
vention, as compared with the current standard of care, on
health outcomes of community children. We aimed to test
the hypothesis that the prevalence of anemia, an established
proxy for malaria-associated health outcomes in children
under 5 years of age, would be lower in intervention clusters,
than in control clusters. We also conducted a mixed-methods
process evaluation alongside the main trial to further our
understanding about the implementation, mechanisms of effect,
and context of the intervention.24
MATERIALS AND METHODS
Study design. The PRIME study was a cluster-randomized
trial conducted in Tororo district, Uganda, a rural area
with intense malaria transmission (estimated entomologic
inoculation rate of 125 infective bites per person-year).25
Twenty government-run health centers (level II and III) in
seven subcounties were included in the study (Figure 1).
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The cluster-randomized design was selected because the inter-
vention was implemented at health centers, whereas the pri-
mary outcome was measured at the community level. The trial
was approved by the Ugandan National Council for Science
and Technology (UNCST Ref HS 794), the Makerere Uni-
versity School of Medicine Research and Ethics Committee
(SOMREC Ref 2010-108), the London School of Hygiene
and Tropical Medicine Ethics Committee (LSHTM Ref 5779),
and the University of California San Francisco Committee on
Human Research (UCSF CHR Ref 006160). The trial proto-
cols have been published previously.23,24 This trial is registered
at Clinicaltrials.gov (NCT01024426).
Participants. From 2009 to 2010, all health centers and
households in the study area were enumerated and mapped
using handheld global positioning system receivers (Garmin
eTrex Legend H®, Garmin, Olathe, KS). Of 22 health cen-
ters in the study area, two pairs of health centers had sub-
stantially overlapping catchment areas; one facility from
each pair was randomly excluded. All other health centers
were eligible for participation. Households located within
2 km of the selected health centers formed the clusters. If
a household was within 2 km of more than one health cen-
ter, the household was assigned to the cluster of the closest
health center. Before the start of the study, study personnel
met with health leaders, health center in-charges, and com-
munity representatives to inform them about the study. An
information sheet was used to describe the intervention, and
verbal consent to participate in the study was obtained from
the health center in-charges.
Randomization and masking. The 20 public health centers
and their surrounding households formed the clusters that
served as the units of randomization, and were assigned in
a 1:1 ratio to intervention or control. Health centers were
stratified by level, and restricted randomization was used to
ensure balance on geographical location and cluster size.
The trial statistician generated the allocation sequence using
random number generation in R (http://www.r-project.org/),
and assigned health centers to study arms. Study personnel
enrolled health centers after randomization; allocation was
not masked.
PRIME intervention. Our formative research included a
household survey, situational analysis of government-run
health centers, and qualitative assessment of health workers’
and community members’ experiences at health centers.12,21
We considered our findings in the context of literature on
previous interventions and theories of behavior change and
FIGURE 1. PRIME study area, health centers, and clusters in Tororo, Uganda.
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adult learning, identifying approaches that could be evaluated
within a randomized controlled trial.22 The PRIME interven-
tion included 1) training in-charges in health center manage-
ment, 2) training health workers in fever case management
and use of mRDTs, 3) training health workers in patient-
centered services, and 4) ensuring adequate supplies of mRDTs
and artemether–lumefantrine (AL). We also articulated two
complementary intervention theories, a program theory and an
implementation theory, to outline why and how we hypothe-
sized the PRIME intervention components would combine to
produce desired outcomes.22
The manuals for delivering the intervention are available
online at www.actconsortium.org. The intervention was
designed to stimulate behavior change and build capacity
through training of in-charges and health workers using adult
learning techniques, and to ensure adequate supply of drugs
and diagnostics at public health centers. Training sessions
were led by skilled trainers, and were delivered over approx-
imately 8–10 weeks in May–June 2011, completing by July 1,
2011, the start date of the evaluation period. Support for
mRDTs and AL continued for the duration of the trial.
Cross-sectional community surveys. Community surveys
were conducted at baseline, and 2 years later, in children
from randomly selected households in each cluster. Using
the census database, a random sample of households with at
least one child under 15 years of age was selected to gener-
ate a list for each cluster of households to be approached.
Separate recruitment lists were generated for each survey.
Study personnel conducted door-to-door recruitment that
continued until the target sample size for participants was
reached for each cluster. At each household, one child under
5 years of age and one 5–15 years of age were eligible for
participation. If multiple children of appropriate age resided
in the household, one child from each age category was ran-
domly selected for recruitment. Selection criteria included
1) appropriate age, 2) agreement of parent/guardian to pro-
vide written informed consent, 3) agreement of child aged
eight years or older to provide written assent, and 4) ability
to locate child.
Participating children underwent a history taking and
examination. Blood was collected by finger prick for thick
blood smear and hemoglobin. Primary caregivers were asked
about bednet use and management of febrile children. In the
final survey, all women of child-bearing age (13–49 years) in
the household were asked to provide birth histories to esti-
mate under-five all-cause mortality.
Cohort study. A cohort of children under 5 years of age
was enrolled from 25 households randomly selected from
each cluster. A random sample of households with at least
one child under 15 years of age was selected from each clus-
ter to generate a list of households to be approached, similar
to the approach used to generate the list for the community
surveys. Door-to-door recruitment was conducted by study
personnel. All children of appropriate age from a single
household were eligible for screening, which was conducted
at a study clinic. Selection criteria included 1) age < 5 years,
2) agreement of parent/guardian to provide written informed
consent, 3) no intention to relocate during the follow-up
period, and 4) not currently enrolled in another research
study. Children who met the eligibility criteria underwent a
clinical and laboratory evaluation. A finger-prick blood sam-
ple was taken to perform a thick blood smear, and measure
hemoglobin. After the initial enrollment, recruitment into
the cohort was dynamic, and all children who were born,
or moved into, a participating household during the study
period were eligible for recruitment.
Within 2 weeks of cohort enrollment, a household survey
was administered to primary caregivers to gather information
about bednet use and management of febrile children. This
survey was repeated approximately 12 months after enroll-
ment to gather additional information about socioeconomic
status. Cohort households were visited by study personnel
every 2 weeks during the first 2 months, and then monthly.
At each visit, questionnaires were administered to gather
information on the health of participants and management
of any illnesses. Data on serious adverse events (SAEs) were
also collected retrospectively during the monthly visits.
Primary caregivers were asked to keep a diary of health
of study participants for the duration of follow-up, which
allowed caregivers to capture information on their children’s
symptoms. Small incentives (including sugar, soap, or wash-
ing powder) were provided to each household during the
monthly visit. Clinical and laboratory evaluations of cohort
participants were repeated every 6 months, and follow-up
continued for approximately 18 months. The cohort study
was halted early on recommendations from our data and
safety monitoring board, after an interim analysis suggesting
lack of efficacy of the intervention on the cohort primary
outcome of antimalarial treatment incidence density.
Laboratory procedures. Thick blood smears were stained
with 2% Giemsa for 30 minutes and read by experienced
laboratory technologists as previously described.23 For qual-
ity control, all slides were read by a second microscopist and
a third reviewer settled any discrepant readings. Hemoglobin
was measured from finger-prick blood samples using a porta-
ble spectrophotometer (HemoCue, Anglom, Sweden).
Outcomes. The primary outcome for the trial was preva-
lence of anemia (hemoglobin < 11.0 g/dL) in children under
5 years of age, assessed in the final community survey.
Secondary outcomes also assessed in the community survey
were prevalence of anemia in children aged 5–15 years, preva-
lence of parasitemia in children aged under 5 and 5–15 years,
and all-cause under-five mortality. The primary outcome for
the cohort study was treatment incidence density among chil-
dren under 5 years of age assessed at monthly visits. Second-
ary outcomes were incidence of antimalarial treatment,
antibiotic treatment, illness, febrile illness, SAEs, and treat-
ment of fever, all assessed at monthly visits, and anemia and
parasitemia assessed at 6-monthly visits.
Statistical analysis. For the community survey, children
were sampled from each cluster in proportion to the total
cluster size, with harmonic mean of 200 children per cluster
for the two age strata. Assuming control arm anemia preva-
lence of 65% in children under 5 years of age26 and coeffi-
cient of variation k = 0.2, this would give 80% power to
detect an absolute difference in anemia prevalence between
study arms of 17% (or more) at 5% significance level,
allowing for the stratified, cluster-randomized design.27 We
assumed a relatively low coefficient of variation k of 0.2 in
our sample size calculations and found this to be reasonable,
with observed k for the primary outcomes in the community
survey and cohort study of 0.12 and 0.13, respectively. Thus,
our trial had good power to detect any potential effect of
the intervention.
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Sample size for the cohort study was determined by the
number of households to be recruited per cluster, and assum-
ing that the average number of children under 5 years of age
per household in this dynamic cohort would be at least 1.6 at
any one time. We recruited 25 households per cluster to give
at least 400 children in each study arm at any one time.
Assuming control arm treatment incidence of 2.5 treatments
per year;28 and k = 0.2, this would give 80% power to detect
a difference of one treatment per year between study arms
at 5% significance level.
Characteristics of participants in the baseline community
survey and at enrollment into the cohort study were summa-
rized by trial arm. Trial analysis was done at the cluster level.
Cluster-level summary measures (proportions for binary out-
comes, incidence for rate outcomes) were calculated. All-
cause mortality was estimated as the cluster-level probability
of dying between birth and 5 years of age. For cohort out-
comes, data were censored at the age of 5 years. For clini-
cal outcomes (anemia, parasitemia) assessed in the cohort at
6-monthly visits, data from all visits conducted postintervention
were used to calculate cluster-specific proportions. Since the
distributions of cluster-level summaries were positively skewed
for most outcomes, log transformations were applied before
analysis. Crude risk ratios (rate ratios for incidence outcomes)
for the intervention effect were calculated by taking the expo-
nential of the difference in the mean of the cluster-specific log
prevalence (rate) between the two arms. Stratified t tests were
used to calculate P values for the intervention effect, with the
within-stratum between-cluster variance estimated as the
residual mean square from a two-way analysis of variance
of the log prevalences (log rates) on stratum and treatment
arm, including an interaction term. Finally, 95% confidence
intervals (CI) for crude risk (rate) ratios, adjusting for stra-
tum, were calculated from this variance using a t-statistic
with 16 degrees of freedom.
For each outcome, analyses of the effect of the interven-
tion adjusting for prespecified covariates, were also per-
formed. For the community survey, analysis of anemia was
adjusted for baseline cluster-specific anemia prevalence, and
analysis of parasitemia was adjusted for baseline cluster-
specific parasitemia prevalence. For cohort clinical outcomes,
analyses adjusted for preintervention cluster-specific anemia/
parasitemia prevalence were calculated from data collected at
preintervention visits. In addition, we adjusted all analyses for
the individual-level variables which are age, gender, and use
of insecticide-treated nets (ITNs). Adjustment was performed
using a two-stage approach.29 Analysis was done using Stata
version 13 (StataCorp, College Station, Texas).
RESULTS
Recruitment and follow-up. From the census and mapping
survey, a total of 40,127 households were enumerated,
including 17,478 households within the cluster areas (Figure 2).
Of these, 14,613 (83.6%) households had at least one child
under 15 years of age. The baseline cross-sectional community
FIGURE 2. Trial profiles for final cross-sectional community survey and cohort study.
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survey was conducted from December 2010 to June 2011, and
the final survey was carried out from January to April 2013
(Figure 3). Of the 7,170 households visited in the final survey,
2,037 were excluded for the reasons outlined in Figure 2. A
total of 8,766 children were screened, and all were enrolled,
including 4,383 children under 5 years and 4,383 aged 5–15 years.
Initial recruitment for the cohort study was conducted from
December 2010 to March 2011. Of the 745 households visited
for recruitment, 243 were excluded, primarily because they
lacked a child under 5 years of age (215, 88.5%). A total of
992 children were enrolled into the cohort study (Figure 2),
and follow-up continued until October 2012. Forty children
enrolled in the cohort were lost to follow-up, and 73 were cen-
sored at their fifth birthday before the start of the evaluation
period (July 1, 2011); thus, 879 children were included in final
analyses of incidence outcomes (Figure 2).
Baseline characteristics. Characteristics of participants in
the preintervention baseline community survey and the cohort
study were similar across both study arms (Table 1). In the
baseline community survey, anemia was more common in chil-
dren under 5 years of age (2,552, 58.2%) than in those aged
5–15 years (1,016, 23.1%). In contrast, children under 5 years
of age were less likely to have a positive blood smear (2,515,
57.5%) than older children (3,164, 72.0%). At enrollment into
the cohort study, the mean age of participants was 2.0 years
(standard deviation [SD] = 1.5 years); 459 (52.2%) were anemic
with a hemoglobin of < 11 g/dL, and 423 (48.3%) had a posi-
tive thick blood smear. A difference in reported use of ITNs
was noted between the community survey and cohort partici-
pants; ITN use was higher in children under 5 years of age who
participated in the community survey (63.2%) than in those
who were analyzed in the cohort study (45.0%, P < 0.001).
Impact on anemia and parasitemia. In both age groups in
the final community survey, and in the cohort study, there were
no differences in the overall prevalence of anemia between the
study arms, after adjusting for differences in age, gender, ITN
use, and either baseline cluster-level prevalence of anemia
(community survey) or prevalence of anemia in the 6 months
preceding the intervention (cohort study, Table 2). Similar
results were observed for prevalence of parasitemia. In both
age groups in the final community survey, and in the cohort
study, there were no differences in the overall prevalence of
parasitemia between the study arms, after adjusting for differ-
ences in age, gender, ITN use, and either prevalence of para-
sitemia in the baseline survey (final community survey) or
prevalence of parasitemia in the 6 months preceding the inter-
vention (cohort study, Table 2).
Impact on all-cause under-five mortality. In the final com-
munity survey, the all-cause under-five mortality rate was 71.5
per 1,000 live births in the control arm, and 74.1 per 1,000 live
births in the intervention arm (risk ratio [RR] = 1.14; 95%
CI = 0.75–1.73; P = 0.53). When the analysis was stratified
into 5-year bands, all-cause mortality decreased steadily from
123.2 per 1,000 live births before 1995 to 53.0 per 1,000 live
births in 2006–2011 (the period immediately preceding the
trial intervention). In the postintervention period, there were
62 reported under-five deaths; 23 in the control arm (20.7 per
1,000 live births) and 39 in the intervention arm (48.4 per
1,000 live births). The difference between arms was not statis-
tically significant (RR = 1.56; 95% CI = 0.83–2.94; P = 0.16).
Impact on treatment of fever and antimalarial treatment
incidence. In the final community survey, the proportion of
households that reported they had sought care for a febrile
child from a public health center in the prior 2 weeks was no
different in the intervention and control arms (26.0% versus
25.0%, respectively), and was slightly lower than at baseline
(28.3% intervention versus 28.6% control).
In the cohort study, there were no differences between the
study arms in the proportion of fever episodes for which children
were treated with any antimalarial (55.8%) or AL (41.4%), or
in the proportion of fever episodes for which children received
prompt treatment (31.9%), or prompt and effective treatment
(23.8%) (Table 3). Of those children who received an anti-
malarial, 74.1% received AL. A total of 4,211 episodes of anti-
malarial treatment over 819.1 person-years of follow-up were
recorded in the cohort study, for an overall incidence of 5.1 per
person-year (Table 4). After adjusting for anemia, age, gender,
household wealth index, distance to health center, and use of
ITNs at enrollment, there was no difference in antimalarial
treatment incidence between the study arms. Similarly, there
were no differences in incidence of illness or fever episodes, or
incidence of antibiotic treatment (Table 4).
Impact on SAEs. Of the 879 children analyzed in the
cohort study, 94 (10.7%) experienced an SAE; 101 SAEs
were reported in 56 control children versus 75 SAEs in 38
intervention children. The most common SAEs were malaria
related, including severe malaria (N = 78), seizures (N = 27),
and suspected severe malaria (N = 18), followed by gastro-
intestinal events (N = 22). Three deaths occurred, two in the
control group (severe malaria and gastroenteritis, and persis-
tent diarrhea) and one in the intervention (suspected severe
malaria); none were considered to be related to AL. There
was no evidence for a difference in incidence of all SAEs
(0.19 SAEs per child-year versus 0.14; RR = 0.72; 95% CI =
0.36–1.47; P = 0.35) or in incidence of malaria-related SAEs.
DISCUSSION
In this cluster-randomized trial, we set out to evaluate
whether improving perceived barriers to quality health care
along the pathway of effect would lead to better health out-
comes at the community level. The intervention design,
FIGURE 3. Study timeline.
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informed by extensive formative research, targeted real and
perceived quality of care through provision of training and
commodities. The PRIME intervention was delivered success-
fully, and appears to have had a small positive impact on
health worker communication with patients,30 community per-
ceptions of care offered at most of the intervention facilities,31
and appropriate treatment of malaria (C. Chandler, personal
communication). However, we found that the PRIME inter-
vention did not improve malaria-related health outcomes of
children in the study area. Our results call into question the
widely held assumption that improving fever case management
by targeting antimalarial treatment using mRDTs will improve
health outcomes. Even in our idealized trial circumstances,
with the intervention tailored specifically for our study setting,
the PRIME intervention had little effect on community-level
health outcomes.
There are many steps in the pathway of effective malaria
case management; fever or illness must be recognized, health
care sought, a diagnostic test for malaria performed, the cor-
rect diagnosis made, and effective treatment prescribed,
obtained, and administered appropriately (Figure 4). Thus,
there are multiple points in the cascade of care where the
intended process of improvements might fail. Even if positive
effects on fever case management are achieved at health cen-
ters, such effects might not reach all community members.
Our hypothesized pathway of change for the PRIME inter-
vention appears to have failed at two points: 1) at the point
of changing treatment-seeking practice and increasing atten-
dance by community members at public health centers, and
2) at the point of substantially improving fever case manage-
ment compared with the control arm. Although the PRIME
intervention appears to have improved more proximal out-
comes, including health worker communication with patients
(which was rated 10% higher by careseekers consulting with
health workers who had recently participated in the PRIME
intervention compared with those in the standard care arm),30
community perceptions,31 and appropriate treatment of malaria
(C. Chandler, personal communication), these changes seemed
insufficient to shift treatment seeking of community members
toward public health facilities to the degree required for a
community-level effect of the intervention. Improvements
noted at health centers by community members were diluted
by shortfalls in infrastructure and other services provided,
such as clean water or staff numbers, which were beyond the
scope of the PRIME intervention. Community members also
reported positioning themselves for possibilities for care from
other sources such as research and nongovernmental organiza-
tion projects. Although it has been suggested elsewhere that
care seekers will go further for better quality of care,32 in our
setting where people are extremely poor, they have limited
bargaining power to access services that may require more
resources,33 even if known to be superior. Failure to shift
treatment-seeking patterns toward public health centers lim-
ited the effect of the intervention. The PRIME intervention
framed access in terms of priorities for health workers and
patients,21 in line with other models for access such as the
5As: availability, affordability, accessibility, accommodation,
and acceptability.34 In practice, to be successful, the interven-
tion would have needed to address a broader range of issues
to enable improved local access to better health care. To truly
address the inadequacies of health services, a much deeper
engagement with the social and political realities of the health
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system would be required, which is unlikely to be achievable
in small-scale projects.
The PRIME intervention also failed to substantially improve
fever case management at health centers. In theory, introduc-
ing mRDTs will improve targeting of antimalarial treatment to
true malaria cases, and reduce “overprescription” of antima-
larials, thus resulting in better health outcomes.7,8 However, in
our study, introducing mRDTs with the PRIME intervention
increased testing, but did not affect antimalarial treatment.
The proportion of consultations resulting in an ACT prescrip-
tion was similar in both arms, at 64.6% and 63.3% in the
intervention and control arms, respectively (C. Chandler, per-
sonal communication). This was probably due to the intensity
of malaria transmission in Tororo and resulting high test posi-
tivity rate, compounded by the relatively poor specificity of
the mRDTs and subsequent false positive test results in our
study setting.35 Contributing to the lack of effect on fever case
management was the change in the availability of AL across
the study area during the trial period.36 The PRIME interven-
tion was designed in the context of chronic shortage of AL,
when it was plausible that boosting the supply of AL could
have had an impact on health outcomes. But, by the time the
trial was conducted, AL supplies had improved substantially
in both public health centers and in the private sector. In the
final community survey, the proportion of febrile children
treated with an antimalarial who received AL was 90.5%, up
from 66.6% at baseline, but there was no difference between
the study arms (90.2% intervention versus 90.9%), suggesting
improvements occurred outside of the study, independent of
the intervention.
The PRIME intervention aimed to improve malaria-related
outcomes by ensuring the implementation of best practice in
malaria case management. In Tororo, where malaria trans-
mission is very high, the PRIME intervention was insufficient
to reduce anemia and parasitemia in community children.
These results have several implications for researchers and
policy makers. First, the assumption that health outcomes and
malaria burden can be reduced by increasing access to
mRDTs, thereby targeting antimalarial treatment and improv-
ing quality of care, requires further investigation. Further
research is required to evaluate the health impact of mRDTs
in different settings, particularly in areas of high malaria trans-
mission. Second, this study does not rule out the potential for
interventions focusing on public health centers to improve
health outcomes at the community level in other settings,
such as areas with lower malaria transmission, or where com-
munity members have greater power to choose where they
seek health care, or settings with lower access to mRDTs or
ACTs. However, to be effective, such interventions must rec-
ognize and address issues in the pathway to impact that may
TABLE 3
Effect of the PRIME intervention on prompt effective treatment of fever: cohort study results (censoring follow-up at age five years)
Trial arm n /N* Prevalence (%)† Crude risk ratio (95% CI) P value Adjusted risk ratio (95% CI)‡ P value
Treatment of fever with any antimalarial
Control 1,955/3,383 57.7
Intervention 1,742/3,239 54.6 0.95 (0.84–1.07) 0.34 0.94 (0.84–1.06) 0.31
Treatment of fever with AL
Control 1,462/3,383 42.0
Intervention 1,278/3,239 39.6 0.94 (0.77–1.16) 0.55 0.94 (0.78–1.14) 0.49
Prompt treatment of fever§
Control 1,176/3,383 33.9
Intervention 939/3,239 29.0 0.86 (0.68–1.07) 0.16 0.85 (0.68–1.07) 0.17
Prompt effective treatment of fever∥
Control 880/3,383 24.8
Intervention 693/3,239 21.1 0.85 (0.62–1.16) 0.28 0.85 (0.63–1.14) 0.25
AL = artemether–lumefantrine; CI = confidence interval.
*Number of monthly visits with outcome (n)/number of monthly visits (N). After censoring follow-up of cohort children at age 5 years, data from 3,383 monthly questionnaires in 447 children
in the control arm and 3,239 monthly questionnaires in 432 children in the intervention arm were included in the cohort analysis.
†Prevalence calculated as geometric mean of cluster prevalences.
‡Adjusted for anemia, gender, age, household wealth, distance to health facility and use of insecticide-treated nets (ITNs) at enrollment into the cohort.
§Treatment of fever with any antimalarial within 24 hours of onset of symptoms.
∥Treatment of fever with an artemisinin-based combination therapy within 24 hours of onset of symptoms.
TABLE 4
Effect of the PRIME intervention on illness and treatment incidence outcomes: cohort study results (censoring follow-up at age five years)
Trial arm
No. of
children Events
Person-years
of follow-up
Incidence rate
per person-year*
Crude rate ratio
(95% CI) P value
Adjusted rate ratio
(95% CI)† P value
Antimalarial treatment incidence
Control 447 2,197 420.4 5.14
0.96 (0.81–1.14) 0.97 (0.82–1.14) 0.68Intervention 432 2,014 398.7 4.95 0.65
Incidence of illness episodes
Control 447 3,868 420.4 9.03
1.00 (0.80–1.25) 1.02 (0.82–1.28) 0.85Intervention 432 3,707 398.7 9.00 0.98
Incidence of febrile illness episodes
Control 447 3,383 420.4 7.96
0.99 (0.80–1.22) 1.01 (0.82–1.25) 0.91Intervention 432 3,239 398.7 7.85 0.89
Antibiotic treatment incidence
Control 447 2,000 420.4 4.70
1.06 (0.85–1.32) 1.08 (0.86–1.35) 0.49Intervention 432 2,048 398.7 4.97 0.59
CI = confidence interval.
*Incidence rate calculated from geometric mean of cluster incidences.
†Adjusted for anemia, gender, age, household wealth index, distance to health facility, and use of insecticide-treated nets at enrollment into the cohort.
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at first appear beyond the scope of a disease-specific objec-
tive. Third, to improve health care access, fundamental issues
of poverty and lack of care-seeker agency must be addressed,
again requiring engagement with local and national political
economic agendas and norms. Finally, achieving impact on
malaria outcomes in high-transmission settings like Tororo will
require a stronger response to malaria control. Greater coor-
dination across disease silos and between different actors
operating within health systems, as well as across other sectors
that intersect with health and development, is needed. Ulti-
mately, localized approaches to malaria control rather than
the universal application of current policies may be required
to maximize investment in interventions aiming to reduce the
burden of malaria.
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